-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BbSvZoZNJOUixu+FEyHk1yHbEsdH5lQA11qQKW4NQEwn/rQyx5H4ABVqyqPL5aGJ
 iDBBQ8/fEvFFi72kqxH30g==

<SEC-DOCUMENT>0000318306-07-000035.txt : 20070605
<SEC-HEADER>0000318306-07-000035.hdr.sgml : 20070605
<ACCEPTANCE-DATETIME>20070605163344
ACCESSION NUMBER:		0000318306-07-000035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070604
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070605
DATE AS OF CHANGE:		20070605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACCESS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		07901394

	BUSINESS ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX CORP/WY
		DATE OF NAME CHANGE:	19831102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8k-158.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>

  <head>
    <title>r8k-158.htm</title>
<!-- Licensed to: Access Pharmaceuticals, Inc.-->
<!-- Document Created using EDGARizer 3.9.9.131 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
        <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      </div>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <div>&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1234px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1029" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div align="center">UNITED STATES <br>SECURITIES AND EXCHANGE
                COMMISSION<br>Washington, D.C.20549</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1234px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" width="1031" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>FORM
                8-K</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1233px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" width="1018" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>CURRENT
                REPORT <br>Pursuant to Section 13 or 15(d) of
                the<br>Securities Exchange Act of 1934</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1233px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1025" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">Date
                of
                Report (Date of earliest event reported):&#160;<strong>June 4,
                2007</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1232px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>ACCESS
                PHARMACEUTICALS, INC.</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Exact
                name of registrant as specified in its charter)</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1070px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 33%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>Delaware</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 33%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>0-9314</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 16%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>83-0221517</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td valign="top" width="406" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="418" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="208" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="406" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(State
                or other jurisdiction <br>of incorporation)</div>
            </td>
            <td valign="top" width="418" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Commission<br>File
                Number) </div>
            </td>
            <td valign="top" width="208" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(IRS
                Employer<br>Identification No.) </div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1084px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" width="438" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>2600
                Stemmons Freeway, Suite 176<br>Dallas,
                Texas</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="346" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="287" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center"><strong>75207</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td valign="top" width="438" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="346" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="287" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="438" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Address
                of principal executive offices)</div>
            </td>
            <td valign="top" width="346" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
            </td>
            <td valign="top" width="287" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center">(Zip
                Code)</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1124px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" width="444" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">Registrant's telephone number, including
                area code:</div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="246" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center">&#160;&#160;<strong>(214)
                905-5100</strong></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="bottom" width="434" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="444" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
            </td>
            <td valign="top" width="246" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
            <td valign="top" width="434" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1226px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1085px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td width="1085" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1085px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Former
                name or former address, if changed since last report)
</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1225px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1081" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Check the appropriate box below if
                the
                Form 8-K filing is intended to simultaneously satisfy the filing
                obligation of the registrant under any of the following provisions
                (see
                General Instruction A.2. below): </div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1212px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 4%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/x/</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 80%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Written communications pursuant to
                Rule
                425 under the Securities Act (17 CFR 230.425) </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 4%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 80%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Soliciting material pursuant to Rule
                14a-12 under the Exchange Act (17 CFR 240.14a-12) </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="610" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 81%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Pre-commencement communications pursuant
                to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="610" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 82%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Pre-commencement communications pursuant
                to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div>
          <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
          <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div><br>&#160;

      <div><strong>Item 8.01. Other Events</strong></div>
      <div>&#160;</div>
      <div>On June 4, 2007, Access issued a press release announcing&#160;data
        regarding Angiolix presented at ASCO Oncology Conference.

        <div>&#160;</div>
        <div style="MARGIN: 0in 0in 0pt">&#160;</div>
        <div style="MARGIN: 0in 0in 0pt">The full text of the press release is furnished
          as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
          herein by
          reference.</div>
        <div>&#160;</div>
        <div style="MARGIN: 0in 0in 0pt">&#160;</div>
        <div>&#160;</div>
        <div><strong>Item 9.01. Financial Statements and Exhibits.</strong></div>
      </div>
      <div>&#160;</div>
      <div>
        <div>(d) Exhibits.</div>
        <div>&#160;</div>
        <div>&#160;</div>
      </div>
    </div>
    <div><strong>Exhibit No.<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;Description</font></strong></div>
    <div>&#160;</div>
    <div>
      <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt; TEXT-ALIGN: left" align="center">99.1<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;</font>Press
        release issued by Access
        Pharmaceuticals, Inc. and Somanta Pharmaceuticals, Inc. dated&#160;June 4, 2007.
</div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1231px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1231" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div align="center">SIGNATURES </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>Pursuant to the requirements of the
      Securities Exchange Act of 1934, the registrant has duly caused this report
      to
      be signed on its behalf by the undersigned hereunto duly authorized. <br></div>
    <div>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1227px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 44%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 152%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">ACCESS PHARMACEUTICALS, INC.</div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1226px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 39%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 5%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 5%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">By: </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 147%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;/s/ Stephen B. Thompson</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="48" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="234" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="30" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="30" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="884" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt">&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1223px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 56%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 35%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Stephen B. Thompson</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 111%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 56%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 35%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Vice President, Chief Financial
                Officer</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 111%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>Date:&#160; June 4, 2007<br></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt; TEXT-ALIGN: center" align="center"><br><strong>Exhibit
      Index</strong></div>
    <div>&#160;</div>
    <div><strong>Exhibit No.<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;Description</strong></div>
    <div>&#160;</div>
    <div>99.1<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;Press
      release issued
      by Access Pharmaceuticals, Inc. and Somanta Pharmaceuticals, Inc. dated June
      4,
      2007.</div>
    <div>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1217px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1217" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: black" align="center" noshade size="5" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br><br><br></div>
    <div>&#160;</div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>r8k-159.htm
<DESCRIPTION>PRESS RELEASE JUNE 4, 2007
<TEXT>
<html>

  <head>
    <title>Unassociated Document</title>
<!-- Licensed to: Access Pharmaceuticals, Inc.-->
<!-- Document Created using EDGARizer 3.9.9.131 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      EXHIBIT 99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div>&#160;</div>
    <div>Access Logo<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2"
 style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;</font></font>&#160;SOMANTA
      Logo<br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>ACCESS/SOMANTA
      NEWS</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Contact:
      Company</u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#16
0;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<u>Contact: Investor Relations</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Stephen
      B.
      Thompson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Donald
      C. Weinberger/Alisa Steinberg (media)</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Vice
      President, Chief Financial
      Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Wolfe Axelrod Weinberger Assoc. LLC</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Access
      Pharmaceuticals,
      Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(212)
      370-4500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>(214)
      905-5100</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>&#160;Andrew
      Hellman, CEOcast, Inc. for Access
      Pharmaceuticals&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>&#160;(212)
      732-4300&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>ACCESS
      AND SOMANTA ANNOUNCE DATA TO BE PRESENTED</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>ON
      ANGIOLIX AT ASCO ONCOLOGY CONFERENCE</u></strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Pre-clinical
      Data Suggests Angiolix Can Inhibit Breast Cancer Growth By
      75%</u></strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font style="DISPLAY: inline; FONT-SIZE: 10pt;"><strong>DALLAS,
      TX &amp; IRVINE, CA,
      June 4, 2007, ACCESS PHARMACEUTICALS, INC. (OTC BB: ACCP)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">&#160;</font>and
<font style="DISPLAY: inline; FONT-SIZE: 10pt;"><strong>SOMANTA
      PHARMACEUTICALS,
      INC.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt;"><strong> (OTC
      BB: SMPM)</strong></font> announced today that a scientific abstract
      outlining&#160;&#160;new preclinical efficacy data for Somanta&#8217;s Angiolix has
      been selected for publication in the Proceedings of the 43rd American Society
      of
      Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 1-5,
      2007. The data, in a study conducted using mouse models, shows that Angiolix
      has
      been able to achieve more than 75% growth inhibition of human breast cancer
      growing as xenografts in mouse.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">ASCO&#8217;s
      annual meeting is the world's premier oncology conference providing information
      on the latest developments in cancer treatment.&#160;&#160;As previously
      announced Access and Somanta have signed a definitive merger agreement for
      Access to acquire Somanta as a step in the creation of a combined company with
      a
      broad cancer-focused portfolio in which Angiolix will be a major
      program.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Angiolix
      is a humanized monoclonal antibody that recognizes a migrating adhesion molecule
      called Lactadherin. Somanta's recent data suggests that tumor cells express
      Lactadherin which is a factor in the growth of tumor vasculature. Several
      existing or potential anti-cancer drugs (such as Avastin) seek to block tumor
      vascularization by blocking a signaling protein know as vascular endothelial
      <u>growth factor</u> (VEGF).&#160;&#160;The binding of Angiolix to Lactadherin
      is thought to cause a VEGF-independent integrin receptor signaling cascade
      that
      blocks vascular endothelial cell proliferation. Due to its ability to neutralize
      Lactadherin-integrin receptor binding, Angiolix may be able to specifically
      target breast cancer cells and thereby cause tumor suppression by blocking
      the
      growth of tumor vasculature.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Dr.
      Agamemnon Epenetos, CEO of Somanta and a coauthor of the Angiolix abstract
      commented, &#8220;We are pleased to be presenting data on Angiolix at this year&#8217;s ASCO
      conference. The preclinical data shows exciting results in a widely used model
      of breast cancer. By targeting tumor vascularization, Angiolix has the potential
      to cause tumor regression and prevent recurrence of growth.&#8221;</font></div>
    <div><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        <div style="WIDTH: 100%" align="left">&#160;&#160;&#160;&#160;&#160;&#160;

          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Access
            Pharmaceuticals, Inc.</strong></font>&#160;&#160;&#160;&#160;&#160;&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Page
          2</strong></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;

          <div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </div>
      </div>
    </div><br>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">&#8220;On
      behalf of both companies we are grateful for the opportunity to present data
      at
      this year&#8217;s ASCO Conference,&#8221; added Stephen R. Seiler, Access&#8217; President and
      CEO.&#160;&#160;&#8220;Recent studies indicate that Angiolix has the potential to
      choke off blood flow to breast tumors, which inherently causes tumor
      regression."</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      Access</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Access
      Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops
      and
      commercializes propriety products for the treatment and supportive care of
      cancer patients. Access' products include ProLindac&#8482;, currently in Phase II
      clinical testing of patients with ovarian cancer and MuGard&#8482; for the management
      of patients with mucositis. The Company also has other advanced drug delivery
      technologies including Cobalamin&#8482;-mediated targeted delivery and oral drug
      delivery. For additional information on Access Pharmaceuticals, please visit
      our
      website at <u>http://www.accesspharma.com</u> .</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>This
      press release contains certain statements that are forward-looking within the
      meaning of Section 27a of the Securities</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>Act
      of 1933, as amended, and that involve risks and uncertainties, including
      statements relating to the efficacy and method of action of Angiolix, the value
      of our products in the market, our ability to achieve clinical and commercial
      success, our ability to successfully develop marketed products and the ability
      to obtain the approvals of Somanta&#8217;s stockholders, to obtain or meet the closing
      conditions in the merger agreement, including applicable regulatory and tax
      requirements, and to otherwise complete the merger in a timely manner. These
      statements are subject to numerous risks, including but not limited to the
      risks
      detailed in Access&#8217; and Somanta&#8217;s Annual Report on Form 10-KSB&#160;&#160;and
      other reports filed by Access and Somanta with the Securities and Exchange
      Commission.</em></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">###</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br></body>
</html>




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
